Octave (US)

United States - Menlo Park, California

• 27/07/2023
• Series B
• $30,000,000

Octave’s Precision Care Solution is the first-of-its-kind that accurately and objectively measures, and helps manage, complex and high-cost neurodegenerative diseases, starting with multiple sclerosis. Octave developed the first and only multivariate blood test to measure MS disease activity, enhanced MRI analytics and protocols, and a digital clinical program with Octave MS care partners to provide continuity of care.

Provider: The solution provides neurologists with a longitudinal and holistic perspective of the patient along with comprehensive and actionable insights, enabling more confident and informed care decisions.

Payer: The integrated and multi-dimensional approach allows payers to reduce total cost of care by optimizing healthcare medications and utilization (hospitalizations, ER visits, MRIs, labs).

Pharma: Octave enables pharma to optimize the entire lifecycle of drug discovery & development as well as clinical trials and post marketing with real world evidence.

Through purposeful problem solving and innovative technologies, Octave’s platform generates, analyzes and combines data to create a new paradigm of MS care, leading to improved patient outcomes.

Related People

William HagstromFounder

United States - South San Francisco, California

N/A

LinkedIn https://www.linkedin.com/in/william-hagstrom-a64b1943/